Amneal Pharmaceuticals, Inc. Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc.

AMRX

Classificação em ações #3013
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is... Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Preço da ação
$19.07
Última sincronização: 2026-10-16
Valor de mercado
$6.09B
Variação (1 dia)
-0.94%
Variação (1 ano)
92.24%
País
US
Negociar Amneal Pharmaceuticals, Inc. (AMRX)

Categoria

Healthcare
Margem Operacional de Amneal Pharmaceuticals, Inc. (AMRX)
Margem Operacional em October 2026 TTM: 12.93%
De acordo com os relatórios financeiros mais recentes e o preço das ações da Amneal Pharmaceuticals, Inc., a margem operacional atual (TTM) é 12.93%. No final de 2023, a margem operacional era 8.54%.
Histórico da Margem Operacional da Amneal Pharmaceuticals, Inc. de 2014 a 2026
Margem Operacional no final de cada ano
Ano Margem Operacional Alterar
2026 (TTM) 12.93% 44.96%
2024 8.92% 4.45%
2023 8.54% -299.07%
2022 -4.29% -158.85%
2021 7.29% 59.52%
2020 4.57% -154.08%
2019 -8.45% 616.10%
2018 -1.18% -104.98%
2017 23.71% -15.26%
2016 27.98% 6.67%
2015 26.23% -7.58%
2014 28.38% 0.00%
Margem Operacional de empresas semelhantes ou concorrentes
Empresa Margem Operacional Diferença na Margem Operacional País
0.00% -
DE
0.00% -
DE
0.00% -
JP
0.00% -
CH
22.93% -98.23%
IN
O que é a Margem Operacional de uma empresa?
A Margem Operacional é um indicador essencial para avaliar a rentabilidade de uma empresa. Margens operacionais mais altas geralmente são melhores, pois mostram que uma empresa consegue vender seus produtos ou serviços por muito mais do que o custo de produzi-los. É calculada dividindo os lucros da empresa pela sua receita.